Breaking Down SG&A Expenses: Amgen Inc. vs argenx SE

A Comparative Analysis of SG&A Expenses: Amgen Inc. vs. argenx SE

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Amgen Inc. and argenx SE from 2014 to 2023. Over this period, Amgen Inc. consistently demonstrated robust financial management, with SG&A expenses growing by approximately 31% from 2014 to 2023. In contrast, argenx SE, a rising star in the biotech sector, exhibited a staggering increase of over 16,600% in SG&A expenses, reflecting its rapid expansion and investment in growth. By 2023, Amgen's SG&A expenses were nearly 9 times higher than argenx's, highlighting the scale of its operations. This financial snapshot not only underscores the strategic priorities of these companies but also offers insights into their market positioning and future trajectories.